Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Linsitinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sling's oral Tepezza rival hits goal in thyroid eye disease, Ph 3
    Sling's oral Tepezza rival hits goal in thyroid eye disease, Ph 3

    15 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sling-therapeutics-announces-positive-topline-results-from-phase-2b3-lids-clinical-trial-of-oral-small-molecule-linsitinib-in-patients-with-thyroid-eye-disease-302350327.html

    PR NEWSWIRE
    15 Jan 2025
    Share Share
    Sling To Present Ph 2b/3 Linsitinib Results For Thyroid Eye Disease
    Sling To Present Ph 2b/3 Linsitinib Results For Thyroid Eye Disease

    13 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sling-therapeutics-to-announce-topline-results-from-phase-2b3-lids-clinical-trial-of-oral-small-molecule-linsitinib-in-patients-with-thyroid-eye-disease-at-the-43rd-annual-jp-morgan-healthcare-conference-302348913.html

    PR NEWSWIRE
    13 Jan 2025
    Share Share